Identification of atypical ATRNL1 insertion to EML4-ALK fusion gene in NSCLC

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00083615" target="_blank" >RIV/00216224:14110/15:00083615 - isvavai.cz</a>
Alternative codes found
RIV/65269705:_____/15:00061643
Result on the web
<a href="http://dx.doi.org/10.1016/j.lungcan.2015.01.002" target="_blank" >http://dx.doi.org/10.1016/j.lungcan.2015.01.002</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.lungcan.2015.01.002" target="_blank" >10.1016/j.lungcan.2015.01.002</a>

Result language
angličtina
Original language name
Identification of atypical ATRNL1 insertion to EML4-ALK fusion gene in NSCLC
Original language description
We herein present a rare case of an EML4-ALK positive patient. A 61-year-old man was diagnosed with locoregional non-small cell lung cancer (NSCLC). No EGFR mutations were detected, and therefore the ALK rearrangement was evaluated using immunohistochemistry (IHC), fluorescence in situ hybridization (FISH) and the reverse transcription PCR (RT-PCR) method for EML4-ALK. All methods showed a positive result and, therefore, the patient was treated with crizotinib with a good therapeutic response. However,a detailed RT-PCR analysis and sequencing revealed an unexpected 138 bp insertion of attractin-like 1 (ATRNL1) gene into the EML4-ALK fusion gene. In our case, the positive therapeutic response suggests that ATRNL1 insertion does not affect EML4-ALK's sensitivity to crizotinib.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)